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MicroRNAs have been reported to play critical roles in various cancers, but there has been no study
on the role of miR-889 in cancers. Here, we report that over-expression of miR-889 leads to rapid
proliferation of EC109 and EC9706 cells in vitro and in vivo by inducing cells into S-phase. Using
bioinformatics methods, DAB2IP was further conﬁrmed to be a direct target of miR-889. In addition,
the expression of DAB2IP, which was negatively correlated with that of miR-889, was signiﬁcantly
associated with clinicopathological features of ESCC patients. In conclusion, miR-889 is an
important regulator in ESCC and both miR-889 and DAB2IP may serve as promising biomarkers
and therapeutic targets in patients with ESCC.
 2015 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Esophageal squamous cell carcinoma (ESCC) is one of the most
malignant gastrointestinal cancers worldwide [1]. Although many
antitumor therapies have been used in patients with ESCC, the
prognosis and the overall survival remain poor [1,2].
MicroRNAs (miRNAs) are 20-25-nt-long highly conserved non-
coding RNAs that bind to sequences within the 30 untranslated
region (30 UTR) of mRNAs and post-transcriptionally regulate the
expression of target genes [3,4]. Recent studies have revealed that
microRNAs are involved in a broad range of biological processes
through their regulation of complex signal transduction pathways
[5,6]. More than 50% of human miRNAs are located at fragile sites
and genomic regions involved in cancers and can lead to the dys-
regulation of oncogenes and tumor suppressors [7]. There havebeen only two studies on miR-889, one in pulmonary tuberculosis
(TB) [8] and one in colorectal cancer, which reported that the
underexpression of miR-889 was signiﬁcantly associated with
improved progression-free or overall survival of patients [9], but
there have been no studies on the function of miR-889 in ESCC.
Thus, we chose to study miR-889.
DOC-2/DAB2 interactive protein (DAB2IP), also known as ASK1
interacting protein (AIP1), located on chromosome 9 (q33.1-q33.3)
is a member of the Ras-GTPase activating protein (Ras-GAP) family
[10,11]. Most studies of DAB2IP have been conducted in prostate
cancer (PCa), and the low expression of DAB2IP has been shown
to affect proliferation, survival, apoptosis and EMT through several
signaling pathways, including Ras-ERK, ASK-JNK, and PI3K-Akt, in
PCa cells [12–14]. Moreover, the downregulation of DAB2IP is cor-
related with resistance to chemo- and radiotherapy in PCa cells
[15,16]. In addition, although the downregulation of DAB2IP is
not observed in ESCC, it is seen in bladder cancer [17], hep-
atocellular carcinoma [18], medulloblastoma [10], lung cancer
[19] and pancreatic cancer [20]. DAB2IP downregulation in various
cancers results from aberrant epigenetic regulation of its promoter
due to DNA hypermethylation and/or histone modiﬁcation by
histone methyltransferase [18,21]. The above data suggest that
DAB2IP functions as a tumor suppressor and could be a prognostic
factor in cancers.
However, neither the relationship between miR-889 and
DAB2IP nor their expression and biological function has been
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and expression of miR-889 in ESCC cells. We then veriﬁed that
DAB2IP was a target of miR-889 and correlated with the
clinicopathological features of ESCC patients. Altogether, our study
suggests that miR-889 is an oncogene of ESCC and could be
targeted for cancer therapy.
2. Materials and methods
2.1. Cell culture and clinical specimens
SK-BR-3, PC1, HeLa and HEK293T cell lines were purchased
from the Chinese Academy of Science cell bank (Shanghai,
China). EC9706, EC109 and KYSE150 cells were kindly provided
by the Central Laboratory, Tongji University Afﬁliated People’s
10th Hospital (Shanghai, China). All of the cells were cultured in
high-glucose Dulbecco’s modiﬁed Eagle’s medium (DMEM;
Hyclone, Logan, UT) supplemented with 10% fetal bovine serum
(FBS; Gibco-BRL Life Technologies, Paisley, UK) and antibiotics
(100 U/mL penicillin and 100 U/mL streptomycin; Gibco-BRL,
USA) at 37 C with 5% CO2 in a humidiﬁed incubator.
The Institutional Review Board approved the tissue procure-
ment protocol used in study, and the appropriate informed consent
was obtained from all patients. Pair-matched tumors and adjacent
non-tumor esophageal tissue samples were obtained from the
Department of Pathology, Anyang Tumor Hospital, Fourth
Afﬁliated Hospital of Henan University of Science and Technology.
2.2. Plasmid construction
For the luciferase reporter assay, the human wt-30UTR of the
DAB2IP gene was ampliﬁed by PCR using the primers in
Supplementary Table S1. The cDNA was cloned into the XhoI/
NotI site of the psiCHECK2 vector (c8021, Promega, Madison, WI,
USA), downstream of the Renilla luciferase gene, to generate the
psiCHECK2-wt-DAB2IP-30UTR vector. The mut-30UTR of the
DAB2IP gene was obtained using a KOD-Plus-Mutagenesis kit
(F0936K, TOYOBO, Japan) according to the manufacturer’s
protocol.
For the DAB2IP-overexpressing plasmid, the human DAB2IP-
CDS was ampliﬁed using the primers in Supplementary Table S1
and cloned into the XhoI/EcoRI site of the pcDNA3.1 vector.
2.3. Cell transfection
A total of 1.5  105 ESCC cells were seeded into 6-well plates
24 h prior to transfection. Lipofectamine 2000 transfection reagent
(3 ll) and Opti-MEM Medium (Invitrogen, Carlsbad, CA, USA) were
used for the transient transfection of microRNA mimics, Anti-miR
inhibitor mimics (Genepharma, Shanghai, China), and si-DAB2IP
(AM16708, Life Tech, USA) according to the manufacturer’s
instructions. The ﬁnal concentration of microRNA or siRNA used
in our study was 50 nM. The transfection of plasmid (pcDNA3.1
and pcDNA3.1-DAB2IP) was similar to that of RNA, except that
the cells were seeded at 2.5  105/well, and 4 ll Lipofectamine
2000 and 2 lg plasmid were used for the transfection.
2.4. RNA isolation and quantitative reverse transcriptase PCR
Total RNA from patient tissue samples and cell lines was
extracted by TRIzol according to the manufacturer’s protocol
(Invitrogen, USA). Reverse transcription was performed using a
PrimeScript RT regent kit (RR037A, Takara Bio Inc., Otsu, Shiga,
Japan). The expression of mature miRNAs was assayed using a
MicroRNA reverse transcription kit (Promega, Madison, WI, USA).Brieﬂy, 12 ll of a mixture containing 1 lg RNA and DEPC-treated
H2O was held at 65 C for 3 min and then put on ice immediately.
Then, 4 ll of 5 Buffer, 0.5 ll M-MLV, 0.5 ll RNasin, 2 ll dNTPs,
0.5 ll speciﬁc stem-loop RT primer and 0.5 ll U6 RT were added
into the mixture. The 20 ll reactions were incubated as follows:
20 C for 10 min, 42 C for 50 min, 75 C for 5 min, and held at 4 C.
cDNAwas diluted 1:19 with ddH2O. cDNA, upstream and down-
stream primers, SYBR and ddH2O were added into each well of a
96-well plate according to the protocol of the KAPA SYBR FAST
Universal qPCR Kit (KK4601, Kapa Biosystems, MA, USA). The data
were measured using an ABI 7900 HT PCR sequencer (Applied
Biosystems, Foster city, CA, USA), and gene expression was calcu-
lated using the 44Ct method for relative quantization using 18S
or U6 as endogenous reference genes. The primers are provided
in Supplementary Table S1.
2.5. MTT assay
A total of 1000 cells transfected with synthesized oligonu-
cleotides were seeded into each well of a 96-well plate. After 0 h,
48 h, 72 h, and 96 h, 20 ll MTT was added into each well and incu-
bated at 37 C for 4 h. The mediumwas removed, and 150 ll DMSO
was added and incubated at 37 C for 10 min to dissolve the crys-
tals. The absorbance values were read at a wavelength of 490 nm.
2.6. Colony formation assay
A total of 500 cells were seeded into each well of a 6-well plate.
Ten days later, the cells were washed with PBS, ﬁxed with 95%
ethanol for 10 min and then stained with 0.1% crystal violet for
15 min. Cells were washed with water and then observed by phase
contrast microscopy (Leica, German).
2.7. Cell cycle assay
A total of 9  104 transfected cells were seeded into 6-well
plates and incubated in serum-deprived medium (0.2% FBS) for cell
synchronization. Subsequently, cells were harvested at 24 h after
incubating with complete medium. The cells were stained with
propidium iodide (PI) (550825, BD Biosciences, San Diego, CA,
USA) and examined with a FACS ﬂow cytometer. Data were ana-
lyzed with ModFit software (BD Biosciences, San Jose, CA, USA).
2.8. EdU assay
A total of 1.2  105 transfected cells were plated into 6-well
plates, and DNA synthesis was assessed with a Cell-Light™ EdU
Apollo488 In Vitro Imaging Kit (C10310-3, RiboBio, Guangzhou,
China). Then, nuclei were stained with DAPI (Invitrogen). Finally,
cells were visualized and counted with a ﬂuorescent microscope
(Leica, German). The EdU labeling index was calculated as EdU-
positive cells/total DAPI-positive cells.
2.9. Western blot
Cells were harvested and lysed in RIPA lysis buffer (Beyotime
Institute of Biotechnology, China) containing PMSF, cocktail and
PhosStop (Roche Applied Science). Total protein was measured
with a BCA Protein Quantitation kit (Beyotime, China). Equivalent
amounts of total protein extract were separated by SDS–PAGE gels
and transferred to nitrocellulose membranes (Millipore, Billercia,
MA, USA). Then, the blots were blocked with 5% fat free milk for
1 h and incubated with primary antibodies for b-actin (Santa
Cruz Biotechnology, Inc., USA), DAB2IP (ab87811, Abcam, UK),
ERK1/2 (4695), Akt (4691), pERK1/2 (T202/Y204, 4376), and pAkt
(Ser473, 4058) (all from Cell Signaling Technologies, Beverly, MA,
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mouse/rabbit immunoglobulin G secondary antibodies (Licor Co.,
Lincoln, NE, USA). The membranes were scanned with an
Odyssey LI-CDR scanner (BD biosciences, USA), and the gray value
was measured using Image J software (National Institutes of Health
(NIH), Bethesda, MD, USA).
2.10. Dual luciferase reporter assay
Different forms of DAB2IP 30-UTR (wt-DAB2IP 30-UTR; mut-
DAB2IP 30-UTR) were cloned downstream of the Renilla luciferase
gene into the psi-CHECK2 vector, and the ﬁreﬂy luciferase gene
was used to normalize the reporter activities.
For the luciferase reporter assay, a total of 5  105 HEK293T
cells were seeded and cultured in 6-well plates the day beforeFig. 1. The functional role and expression of miR-889 in ESCC. (A and B) Growth curves
subclones generated from EC9706 and EC109 cells. (C and D) The effect of miR-889 overe
subclones generated from EC9706 and EC109 cells. Five groups were used, and the vo
expression in human ESCC specimens and corresponding normal tissues (T/N). Fifty pair
N = 2 (blue solid line). Thirty-three pairs had a ratio above 2-fold (left of the blue dashed
distribution of miR-889 expression in clinical specimens. The pie was divided into threetransfection. Cells were co-transfected with 2 lg of the constructed
plasmid together with 75 nMmiR mimics or a scrambled sequence
using 4 ll Lipofectamine 2000 according to the manufacturer’s
protocol (Invitrogen). Cells were lysed and assayed for luciferase
activity at 24 h after transfection using a Dual-Luciferase Assay
kit (E1910, Promega, Madison, WI, USA).
2.11. Immunohistochemistry
Clinical specimens were ﬁxed in 4% paraformaldehyde for 24 h,
dehydrated, embedded in parafﬁn and sliced into 4 lm sections.
The tissue sections were treated with xylene and graded alcohol
and then equilibrated in PBS. Endogenous peroxidase was blocked
with 3% H2O2 diluted in PBS for 10 min. Then, antigen retrieval was
performed by boiling slides for 10 min at a high pressure indetected at various time points by MTT assay in miR-889-overexpressing and NC
xpression on colony formation. (E–H) The in vivo tumor growth of miR-889 and NC
lume (mm2) and weight (mg) of tumors were calculated. (I) The ratio of miR-889
s of tissues were used for the assay, and the ratio was divided into two parts by T/
line), and the others had a ratio below 2-fold (right of the blue dashed line) (J) The
parts by T/N = 0.5 and T/N = 2.
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Non-speciﬁc binding was blocked by incubation with normal goat
serum (1:500, Invitrogen) for 1 h at room temperature; then, the
sections were incubated with anti-DAB2IP antibody (1:200,
ab87811, Abcam, UK) at 4 C overnight. Next, the sections were
washed with PBS and incubated with HRP-conjugated secondary
antibody (K5007, DAKO, Japan) at room temperature for 1 h. The
visualization signal was developed with DAB (DAKO, Japan), and
the nuclei were counterstained with hematoxylin (Beyotime).
The sections were dehydrated, hyalinized and sealed.
The histologic appearance and staining intensity were exam-
ined and scored by two pathologists independently and classiﬁed
as follows: absent (scored as ), weak-positive (scored as +), mod-
erately-positive (scored as ++) and strong-positive (scored as +++).
We classiﬁed 2+ or 3+ expression as positive, and + or  expression
as negative [22].Fig. 2. MiR-889 regulates S-phase cell distribution in ESCC. (A and B) miR-889 enhanced
phase were stained with EdU (green), and the others were stained with DAPI (blue). (C an
was measured by ﬂow cytometry with PI staining.2.12. Xenograft tumor model
For the miR-889 overexpression experiments, EC109/EC9706
cells were infected with lentivirus expressing miR-889 (Genchem
Limited Company, Changzhou, China) or its negative control at
30–50% conﬂuency. A monoclonal population of stably infected
cells was prepared using a limiting dilution assay, and a miR-
889-overexpressing clone was selected by qRT-PCR. Then, stable
EC109/EC9706-miR-889-LV and EC109/EC9706-NC-LV cells
(5106 cells) were inoculated into the left and right ﬂanks of each
nude mouse [22–24]. Five mice were included in each group. The
weight (mg) was measured with an electronic balance, and the vol-
ume of the implanted tumor was measured every 4 days for
4 weeks with a Vernier caliper, using the formula volume
(mm3) = 0.5  length width2 [25]. The animal study was per-
formed in strict accordance with the recommendations in theproliferation by promoting the entry of cells into S-phase. The nuclei of cells in S-
d D) MiR-889 resulted in more S-phase cells. The number of cells in different phases
Y. Xu et al. / FEBS Letters 589 (2015) 1127–1135 1131guidelines for the Animal Care and Use Committee of the Tenth
People’s Hospital of Shanghai.
2.13. Statistical analysis
Statistical analyses were performed using SPSS version 21.0
(SPSS Inc., Chicago, IL, USA). All data are presented as the
mean ± S.D. Statistical signiﬁcance is shown as ⁄(P < 0.05),
⁄⁄(P < 0.01), ⁄⁄⁄(P < 0.001).
3. Results
3.1. miR-889 induces proliferation in vitro and in vivo and is
overexpressed in clinical specimens
To screen miRNAs that are able to promote or inhibit ESCC cell
proliferation, we transfected 300 different miRNAs into EC9706
individually and then detected cell growth by MTT assay. There
were 5 miRNAs, miR-221, miR-222, miR-577, miR-1246 and miR-
889, that signiﬁcantly promoted cell proliferation, whereas 6
miRNAs, miR-143, miR-200a, miR-200c, miR-342-5p, miR-510
and miR-940, suppressed cell proliferation. Because very few stud-
ies of miR-889 have been reported, we focused on the role of miR-
889 in promoting ESCC cell growth. We transfected miR-889 pre-
cursor into 3 ESCC cell lines (EC9706, EC109 and KYSE150) to
increase the levels of ectopic miR-889 (Supplementary Fig. 1BFig. 3. DAB2IP is the target of miR-889. (A) The distribution of miR-889 target genes. Th
DAB2IP expression was inhibited by miR-889 at the mRNA level. Four genes (DAB2IP, SO
examine the expression level between NC and miR-889 subclones using the 18S ribosom
The region of the DAB2IP 30UTR that interacted with miR-889 is identiﬁed by TargetSc
reporter assay and presented as Rluc/Fluc (renilla/luciferase ﬁreﬂy). The Rluc/Fluc value
triplicate. ⁄⁄P < 0.01. (D) miR-889 suppressed the expression of the DAB2IP protein. The ex
reference.right, 2A and C, P < 0.01) and determined that the elevation of
miR-889 signiﬁcantly increased the growth rate of EC9706 and
EC109 from the third day (Fig. 1A and B, P < 0.01), whereas in
KYSE150, the growth rate increased slowly and there was a differ-
ence between NC and miR-889 subclones at the fourth day
(Supplementary Fig. 1B left, P < 0.05). In addition, the proﬁle of
miR-899 expression in the 3 ESCC cell lines was tested, and human
embryonic kidney cell 293T was used as control. Compared to
293T, different cell lines were found to express miR-889 to differ-
ent levels; EC9706 had the lowest expression, followed by EC109,
and KYSE150 had the highest (Supplementary Fig. 1A). Based on
the qRT-PCR results, a miR-889 inhibitor was used to knockdown
endogenous miR-889 in KYSE150 (Supplementary Fig. 1C right,
P < 0.01), which resulted in a slower growth rate than with the
NC (Supplementary Fig. 1C left, P < 0.05). Moreover, miR-889 pro-
moted colony formation in EC9706 and EC109 cells
(Fig. 1C and D). In conclusion, the overexpression of miR-889 pro-
moted proliferation in ESCC cells. Furthermore, we veriﬁed the
effect of miR-889 on cell proliferation in 3 additional cancer cell
lines (SK-BR-3, PC1 and HeLa), revealing that miR-889 promoted
the proliferation of other cancer cells (Supplementary Fig. 3,
P < 0.01).
To verify the effect of miR-889 in vivo in ESCC cells, miR-889-
overexpressing or control cells (Supplementary Fig. 2B and D,
P < 0.01) were subcutaneously injected into nude mice. Four weeks
later, we found that tumors derived from the miR-889 subclonee target genes of miR-889 were divided into groups according to their functions. (B)
X9, WNT5A and MEF2C) that negatively regulate cell proliferation were chosen to
e as an internal reference. (C) The binding site of miR-889 within the DAB2IP 30UTR.
an and highlighted in red. The luciferase activity was measured by dual-luciferase
of control was set as 100%. Each experiment was repeated at least three times in
pression level of DAB2IP was quantiﬁed by western blot using b-actin as an internal
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clone (Fig. 1E–H, P < 0.01), which demonstrated that miR-889
was also a tumor-promoting factor in vivo. In addition, miR-889
was overexpressed in 66% of the tumor specimens relative to nor-
mal tissues (Fig. 1I and J), indicating that the overexpression of
miR-889 is associated with ESCC development.
3.2. Overexpression of miR-889 results in a higher percentage of S-
phase cells
We showed that miR-889 promoted the proliferation of ESCCs
in vitro and vivo and that the proliferation process was always
modulated by the cell cycle. Thus, we next determined which step
of the cell cycle was inﬂuenced by miR-889. First, an EdU assay
revealed that the miR-889 subclone incorporated more EdU com-
pared with the NC subclone (Fig. 2A and B, P < 0.01), indicating thatFig. 4. The knockdown of DAB2IP accelerated the proliferation of ESCC. (A and B) The dow
by MTT assay. (C and D) DAB2IP affected the formation of ESCC cell colonies. (E and F
cytometry was used to measure the number of cells distributed in different phases.miR-889 induced cells into S-phase. Moreover, ﬂow cytometry
revealed that miR-889 strongly increased the percentage of cells
in S-phase (Fig. 2C and D). These data suggested that miR-889
enhanced cell proliferation by affecting the G1-S phase of the cell
cycle.
3.3. DAB2IP is a target of miR-889
As it is known that miRNAs work by inhibiting the expression of
their target genes, we used TargetScanHuman 6.2 and GeneCoDis3
to predict the targets of miR-889 (Fig. 3A) and then chose four
genes (DAB2IP, SOX9, WNT5A and MEGF2C) that had functions
that oppose miR-889 in ESCC for our study. Of the 4 genes, only
DAB2IP was dramatically inhibited by miR-889 (Fig. 3B, P < 0.01).
Therefore, DAB2IP was chosen for further research. We determined
the miR-889 binding site on the 30UTR of DAB2IP (Fig. 3C top) andnregulation of DAB2IP promoted the growth of ESCC. The growth rate was detected
) The knockdown of DAB2IP resulted in a higher percentage of S-phase cells. Flow
Table 1
IHC scores of DAB2IP in miR-889 low or miR-889 high group.
DAB2IPNegative (/+) DAB2IPPositive (++/+++) Total
miR-889 low 4 10 14
miR-889 high 30 6 36
Total 34 16 50
P < 0.001.
The relative expression of miR-889 (T/N) was quantiﬁed using qRT-PCR and nor-
malized by U6 and DAB2IP was evaluated by IHC staining. The histologic appear-
ance and staining intensity were examined and scored as follows: absent (scored as
), weak-positive (scored as +), moderately-positive (scored as ++) and strong-
positive (scored as +++). We classiﬁed 2+ or 3+ expression as DAB2IP Positive, and +
or  expression as DAB2IP Negative; the samples that T/N < 0.5 as miR-889 low and
T/N > 2 as miR-889 high.
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miR-889 co-transfection dramatically decreased the relative luci-
ferase activity (Rluc/Fluc) of the vector encoding the wt-DAB2IP
30UTR, but not the vector with mut-DAB2IP 30UTR. Moreover, the
relative luciferase activity (Rluc/Fluc) remained as high as in the
control group in the presence of an anti-miR-889 inhibitor. In addi-
tion, the expression level of DAB2IP protein in the NC subclone was
higher than that in the miR-889 subclone (Fig. 3D), suggesting that
miR-889 bound to nucleotides 1958–1964 of the DAB2IP 30UTR
and inhibited its expression.
3.4. Knockdown of DAB2IP accelerates the proliferation of ESCC cells
To determine whether the downregulation of DAB2IP could
inﬂuence the proliferation of ESCC cells, 3 siDAB2IP sequences
(siDAB2IP #1, siDAB2IP #2 and siDAB2IP #3) were used to knock
down endogenous DAB2IP, but only one sequence inhibited its
expression (Supplementary Fig. 4, P < 0.01). Cells transfected with
this siDAB2IP appeared to have an increased growth rate
(Fig. 4A and B, P < 0.01), many large colonies (Fig. 4C and D) and
an increased number of cells in S-phase (Fig. 4E and F). Based on
the above results, we concluded that decreased DAB2IP could
induce the proliferation of ESCC cells, which was in agreement
with the effect of miR-889 overexpression. As many studies have
reported that DAB2IP regulates the PI3K/Akt and Ras/ERK path-
ways, which are well characterized and involved in the control of
cell proliferation, we veriﬁed the expression level of 4 proteins
(Akt, p-Akt, ERK1/2 and p-ERK1/2), showing that both of the path-
ways were activated in siDAB2IP cell lines (Supplementary Fig. 5).
3.5. Rescue of DAB2IP in miR-889 overexpressing cells inhibited
proliferation
To test the hypothesis that miR-889 regulates cell proliferation
by targeting DAB2IP, EC109 and EC9706 cells were co-transfected
with a miR-889 precursor and a DAB2IP-expressing vector. AnFig. 5. The rescue of DAB2IP in miR-889-overexpressing cells inhibited proliferation. (A
overexpressing cells. The data were obtained using the MTT assay at 0 h, 48 h, 72 h and
preventing the entry of cells into S-phase. An EdU kit was used for the assay.MTT assay revealed that miR-889 expression increased cell pro-
liferation, whereas this promotion was partially reversed by the
co-overexpression of DAB2IP (Fig. 5A and B, P < 0.01).
Consistently, the increased number of S-phase cells induced by
miR-889 was reversed by co-transfection of DAB2IP
(Fig. 5C and D, P < 0.01). In addition, the qRT-PCR and WB results
demonstrated that overexpression of DAB2IP could indeed rescue
the expression level of DAB2IP decreased by miR-889 in cells
(Supplementary Fig. 6). The observation that the promotion of cell
proliferation induced by miR-889 can be reversed by the
overexpression of DAB2IP suggested that the effect of miR-889
on cell growth is largely mediated by its effect on DAB2IP.
3.6. Effect of DAB2IP and miR-889 on the clinicopathological features
of ESCC
The expression of DAB2IP was noted mainly in the cytoplasm of
cells [17]. In this study, DAB2IP was highly expressed in normal tis-
sues and low-grade ESCC tissues but was expressed at low levels in
high-grade ESCC tissues (Fig. 6A). In addition, 83.3% (30/36) of tis-
sues with high expression of miR-889 had low expression of
DAB2IP compared with only 28.6% (4/14) of tissues with lowand B) The growth rate was inhibited by the overexpression of DAB2IP in miR-889-
96 h after transfection. (C and D) The rescue of DAB2IP inhibited proliferation by
Fig. 6. The correlation between DAB2IP and miR-889 in ESCC tissues and normal esophageal tissues. (A) The expression of DAB2IP in clinical specimens by
immunohistochemistry. (B) The negative correlation between the expression of miR-889 and DAB2IP in 50 ESCC patient samples (r = 0.6407; P < 0.001). The relative
expression of miR-889 and DAB2IP was quantiﬁed using qRT-PCR, normalized to U6 or 18S and analyzed with the Pearson correlation. For comparisons, a two-tailed,
unpaired t-test was used.
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DAB2IP and miR-889 in the 50 tumor samples analyzed with the
Pearson correlation also showed a negative correlation between
the two (Fig. 6B, r = 0.6407, P < 0.001).
The correlation of DAB2IP with the clinicopathologic features of
ESCC is shown in Supplementary Table S2. Low expression of
DAB2IP was signiﬁcantly associated with poor differentiation
(P = 0.047), a high TNM stage (P = 0.033) and a large tumor size
(P = 0.003). No signiﬁcant associations were found between
DAB2IP expression and age, gender, gross pathology, position, or
T and N classiﬁcation (P > 0.05).
4. Discussion
The altered expression of miRNAs leading to changes in cell pro-
liferation, survival and apoptosis underlies many diseases, particu-
larly cancers. Various miRNAs have been reported in different
cancers. However, to our knowledge, this is the ﬁrst study to inves-
tigate the expression level and biological function of miR-889 in
tumors. In this study, we clearly showed that miR-889 functioned
as an oncogene that promoted ESCC proliferation, and we veriﬁed
that DAB2IP was its target gene.
As only one study of miR-889 in tumors, which was in colorec-
tal patients, has been reported, we speculated whether miR-889
had an inﬂuence on other types of cancers. Accordingly, the breast
cancer cell line SK-BR-3, the prostate cancer cell line PC1 and the
cervical cancer cell line HeLa were used for functional research
(Supplementary Fig. 3), and their proliferation was also promoted
by miR-889, suggesting that miR-889 has a common role in
regulating cell proliferation in different types of cancer cells.
DAB2IP is a novel member of the Ras GTPase-activating protein
family and is a unique scaffold protein that balances cell prolifera-
tion, survival and motility pathways. The N-terminal C2 domain is
critical for ASK1 activation pathways, which regulate apoptosis,and the GAP-related domain (GRD) modulates the Ras-mediated
signaling pathways [26]. The C-terminal proline-rich (PR) and
PERIOD-like (PER) domains are critical for modulating PI3K and
Akt activity, respectively [13]. DAB2IP inhibits the Ras pathway
by directly binding to and inactivating H-Ras and R-Ras through
its Ras GTPase activity, and it regulates the ASK1 pathway by
blocking the interaction of ASK1 with its inhibitor 14-3-3 [26,27].
Both the PI3K/Akt pathway (a cascade of anti-apoptotic signals)
and the Ras/ERK pathway are well characterized and involved in
the control of cell proliferation [28]. Thus, in our study, DAB2IP’s
role in inhibiting the Ras pathway might explain why the down-
regulation of DAB2IP by miR-889 can lead to enhancement of
ESCC cell proliferation. To conﬁrm this hypothesis, the expression
levels of ERK1/2, p-ERK1/2, Akt and p-Akt were assessed by west-
ern blotting in cells expressing varying levels of DAB2IP
(Supplementary Fig. 5). The knockdown of the endogenous
DAB2IP gene by siDAB2IP resulted in increased expression and
activation of Akt and ERK1/2, revealing that the two pathways
were involved in miR-889-regulated proliferation. In addition,
DAB2IP can suppress cancer metastasis by preventing the epithe-
lial-to-mesenchymal transition (EMT) through the inhibition of
several pathways, such as the Wnt-b-catenin and Akt-mTOR-
ZEB1 pathways [14,29]. Therefore, we speculate that miR-889
may induce EMT through the Akt-ZEB1 pathway.
Although miR-889 was observed to be overexpressed in ESCC
cells and tissues, the mechanism remains unknown. There are
two main reasons for abnormal versions of microRNAs: one is pro-
moter modiﬁcation [30] and the other is the regulation of interact-
ing proteins [31,32]; however, which one causes the
overexpression of miR-889 should be studied further. There are
several pathways leading to the downregulation of DAB2IP in vari-
ous human cancers: altered epigenetic regulation of its promoter,
such as by DNA hypermethylation and/or histone modiﬁcation
[18,21], inactivation through Akt-mediated phosphorylation and
Y. Xu et al. / FEBS Letters 589 (2015) 1127–1135 1135degradation through SCFFbw7-mediated ubiquitination, degrada-
tion [12] and inhibition by miR-889, which was veriﬁed in our
study. Therefore, we speculated that the feedback loop of Akt can
enhance the inhibition of DAB2IP by miR-889. However, whether
the four DAB2IP downregulation pathways coordinate with each
other should be tested in the future.
Overall, miR-889 is an oncogene that regulates the proliferation,
survival, migration and invasion of ESCC cells by downregulating
DAB2IP, which leads to the alteration of several signaling path-
ways. Moreover, as DAB2IP is associated with the clinicopathologic
features of ESCC and miR-889 is negatively correlated with DAB2IP,
they may both serve as potential biomarkers and therapeutic tar-
gets in ESCC.
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